Search Videos by Topic or Participant
Browse by Series:

Multigene Panel Testing in Breast Cancer

Panelists: Carlos L. Arteaga, MD, Vanderbilt; Adam M. Brufsky, MD, UPMC; Joyce O'Shaugnessy, MD, Texas Oncology; Edith A. Perez, MD, Mayo Clinic; Debu Tripathy, MD, MD Anderson Cancer Center; Denise A. Yardley, MD, Sarah Cannon
Published: Thursday, Jun 18, 2015
For High-Definition, Click
Multigene assays have been utilized to profile genes to identify molecular drivers of cancer and appropriate targeted therapies. At this point, several companies offering multigene panel assessment, using next-generation sequencing. Additionally, many cancer centers are developing their own 400-gene panels, which can be used to guide patients to appropriate clinical trials and emerging therapies.

More often than not, the molecular information obtained from a multigene panel cannot be readily utilized, since a necessary drug may not exist, explains Carlos L. Arteaga, MD. The primary utility of Foundation Medicine’s and similar multigene assays is to triage patients to clinical trials, concurs Debu Tripathy, MD. Readouts may occasionally identify a PI3-kinase mutation that allows clinicians to consider using an mTOR inhibitor, but without firm data at this point, Tripathy says that assay results must be interpreted with caution.

Another challenge in disease management is access to agents, explains Joyce O’Shaughnessy, MD, citing a need for better coverage of medications for exceptional responders.
Slider Left
Slider Right
For High-Definition, Click
Multigene assays have been utilized to profile genes to identify molecular drivers of cancer and appropriate targeted therapies. At this point, several companies offering multigene panel assessment, using next-generation sequencing. Additionally, many cancer centers are developing their own 400-gene panels, which can be used to guide patients to appropriate clinical trials and emerging therapies.

More often than not, the molecular information obtained from a multigene panel cannot be readily utilized, since a necessary drug may not exist, explains Carlos L. Arteaga, MD. The primary utility of Foundation Medicine’s and similar multigene assays is to triage patients to clinical trials, concurs Debu Tripathy, MD. Readouts may occasionally identify a PI3-kinase mutation that allows clinicians to consider using an mTOR inhibitor, but without firm data at this point, Tripathy says that assay results must be interpreted with caution.

Another challenge in disease management is access to agents, explains Joyce O’Shaughnessy, MD, citing a need for better coverage of medications for exceptional responders.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x